Skip to main content
Aptose Biosciences Inc. logo

Aptose Biosciences Inc. — Investor Relations & Filings

Ticker · APS LEI · 5299003EUHV3CD08L949 TSX Professional, scientific and technical activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2026-02-12 Report Publication Anno…
Country CA Canada
Listing TSX APS

About Aptose Biosciences Inc.

https://www.aptose.com/

Aptose Biosciences Inc. is a clinical-stage biotechnology company dedicated to developing precision medicines and first-in-class targeted agents for life-threatening cancers, focusing primarily on hematologic malignancies. The company's strategy involves creating differentiated therapies designed for safe single-agent efficacy across multiple indications and enhanced combination potential without overlapping toxicities. Key investigational agents include Tuspetinib, a potent oral Myeloid Kinase Inhibitor (MKI) targeting SYK, FLT3, and JAK, currently in Phase 1/2 for relapsed or refractory Acute Myeloid Leukemia (AML). The pipeline also features Luxeptinib, a dual-acting Kinome Inhibitor. Luxeptinib acts as a Lymphoid Kinome Inhibitor (LKI) in Phase 1a/b trials for B-cell malignancies (CLL/NHL) by non-covalently inhibiting BTK, and as an MKI in Phase 1a/b trials for AML and high-risk Myelodysplastic Syndromes (MDS) by potently inhibiting FLT3.

Recent filings

Filing Released Lang Actions
Other.pdf
Report Publication Announcement Classification · 1% confidence The document is a short news release (1726 characters) announcing that the company has filed its annual report (Form 40-F) with the SEC and Canadian authorities. It provides links to where the actual report can be found but does not contain the report itself. Per the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2026-02-12 English
Other.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Preliminary Proxy Statement' filed with the SEC on Schedule 14A. It contains a 'Notice of Special Meeting' and detailed information regarding a proposed plan of arrangement (merger/acquisition) involving Aptose Biosciences Inc. and Hanmi Pharmaceutical Co. Ltd. The document is designed to solicit shareholder votes for the upcoming special meeting. According to the provided definitions, materials sent to shareholders to provide information and request votes for meetings are classified as Proxy Solicitation & Information Statement (PSI).
2026-02-12 English
Notice of the meeting and record date - English.pdf
AGM Information Classification · 1% confidence The document is a notice from Computershare to Canadian Securities Regulatory Authorities regarding an upcoming 'Special Meeting' for Aptose Biosciences Inc. It outlines key dates such as the record date, meeting date, and details regarding proxy-related materials and voting security information. This is a standard notification document sent to regulators to initiate the proxy process for a shareholder meeting, which falls under the category of Proxy Solicitation & Information Statement materials.
2026-02-06 English
Notice of the meeting and record date (amended) - English.pdf
AGM Information Classification · 1% confidence The document is a formal notice from Computershare (the transfer agent) to Canadian Securities Regulatory Authorities regarding the cancellation of a Special Meeting of Security Holders for Aptose Biosciences Inc. It provides meeting details, record dates, and security information. Since it is a regulatory notification regarding meeting status and does not contain proxy materials, voting results, or the meeting presentation itself, it falls under the general regulatory filing category.
2026-01-12 English
News release - English.pdf
M&A Activity Classification · 1% confidence The document is a press release announcing the rescheduling of a special meeting of shareholders related to a pending acquisition by Hanmi Pharmaceutical. It discusses the status of regulatory clearance (SEC) and the postponement of the meeting date. While it mentions proxy materials, it is not the proxy statement itself, nor is it a final voting result. It falls under M&A activity (TAR) as it pertains to the progress and procedural updates of a merger/acquisition transaction.
2025-12-19 English
Other.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a Schedule 14A filing, which is the standard SEC form for a Proxy Statement. It contains a Notice of Special Meeting, details regarding a proposed plan of arrangement (merger/acquisition), and instructions for shareholders to vote on these proposals. This document is clearly intended to solicit shareholder votes for an upcoming meeting, fitting the definition of a Proxy Solicitation & Information Statement.
2025-12-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.